LENZ Therapeutics, Inc. $LENZ Shares Bought by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC increased its position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 142.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 87,753 shares of the company’s stock after buying an additional 51,568 shares during the quarter. Lisanti Capital Growth LLC’s holdings in LENZ Therapeutics were worth $4,088,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. raised its position in LENZ Therapeutics by 108.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 1,122,738 shares of the company’s stock worth $32,907,000 after acquiring an additional 585,000 shares in the last quarter. Saturn V Capital Management LP bought a new position in shares of LENZ Therapeutics during the 2nd quarter valued at about $10,033,000. Invesco Ltd. acquired a new position in shares of LENZ Therapeutics in the 2nd quarter worth approximately $7,816,000. Stempoint Capital LP bought a new stake in shares of LENZ Therapeutics in the 2nd quarter worth approximately $5,390,000. Finally, Candriam S.C.A. bought a new position in shares of LENZ Therapeutics in the second quarter valued at $5,020,000. 54.32% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CFO Daniel R. Chevallard bought 2,198 shares of the stock in a transaction on Friday, November 7th. The shares were purchased at an average price of $22.76 per share, for a total transaction of $50,026.48. Following the completion of the purchase, the chief financial officer directly owned 5,386 shares of the company’s stock, valued at $122,585.36. This trade represents a 68.95% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Shawn Olsson sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $26.10, for a total value of $261,000.00. Following the completion of the sale, the insider directly owned 4,733 shares of the company’s stock, valued at approximately $123,531.30. The trade was a 67.87% decrease in their position. The SEC filing for this sale provides additional information. 6.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LENZ. Zacks Research lowered LENZ Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LENZ Therapeutics in a report on Thursday, January 22nd. Raymond James Financial reiterated an “outperform” rating and issued a $50.00 price target (up previously from $40.00) on shares of LENZ Therapeutics in a research report on Monday, October 20th. HC Wainwright restated a “buy” rating on shares of LENZ Therapeutics in a report on Monday, December 15th. Finally, Piper Sandler upped their price objective on shares of LENZ Therapeutics to $67.00 and gave the company an “overweight” rating in a research note on Friday, October 10th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $56.40.

LENZ Therapeutics Price Performance

Shares of LENZ opened at $15.82 on Friday. The business’s 50-day moving average is $20.48 and its 200-day moving average is $30.56. The company has a market capitalization of $495.01 million, a price-to-earnings ratio of -7.50 and a beta of 0.50. LENZ Therapeutics, Inc. has a fifty-two week low of $14.43 and a fifty-two week high of $50.40.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.08. The company had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $4.64 million. Equities research analysts expect that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current fiscal year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.